Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

被引：1
|
作者：
Vaduganathan, Muthiah
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Inzucchi, Silvio E.
Zinman, Bernard
Butler, Javed
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-30-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
30-OR
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial
    Vaduganathan, Muthiah
    Inzucchi, Silvio E.
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Zinman, Bernard
    Butler, Javed
    DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2775 - 2784
  • [2] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
    Bernard Zinman
    Silvio E. Inzucchi
    Christoph Wanner
    Uwe Hehnke
    Jyothis T. George
    Odd Erik Johansen
    David Fitchett
    Diabetologia, 2018, 61 : 1522 - 1527
  • [3] Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial
    Vaduganathan, M.
    Sattar, N.
    Fitchett, D.
    Ofstad, A.
    Brueckmann, M.
    George, J. T.
    Verma, S.
    Mattheus, M.
    Wanner, C.
    Inzucchi, S. E.
    Zinman, B.
    Butler, J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S275 - S275
  • [4] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
  • [5] Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME
    Vaduganathan, Muthiah
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    Butler, Javed
    CIRCULATION, 2020, 142
  • [6] Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    George, Jyothis T.
    Johansen, Odd Erik
    Fitchett, David
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    DIABETOLOGIA, 2018, 61 (07) : 1522 - 1527
  • [7] Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME
    Fisher, Miles
    BRITISH JOURNAL OF DIABETES, 2020, 20 (02): : 138 - 141
  • [8] Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
    Verma, Subodh
    Mazer, C. David
    Al-Omran, Mohammed
    Inzucchi, Silvio E.
    Fitchett, David
    Hehnke, Uwe
    George, Jyothis T.
    Zinman, Bernard
    CIRCULATION, 2018, 137 (04) : 405 - 407
  • [9] Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME
    Jurisic-Erzen, D.
    Johansen, O.
    George, J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    DIABETOLOGIA, 2016, 59 : S349 - S349
  • [10] Empagliflozin in Resistant Hypertension: Findings From the Empa-reg Outcome Trial
    Ferreira, Joao Pedro
    Fitchett, David
    Ofstad, Anne Pernille
    Kraus, Bettina J.
    Wanner, Christoph
    Zwiener, Isabella
    Lauer, Sabine
    George, Jyothis T.
    Rossignol, Patrick
    Zannad, Faiez
    CIRCULATION, 2019, 140
12345